Screening Libraries • Proteins

(S,R,S)-AHPC-Me

Cat. No.: HY-112078 CAS No.: 1948273-02-6 Molecular Formula: $C_{23}H_{32}N_4O_3S$ Molecular Weight: 444.59

Target: Ligands for E3 Ligase

Pathway: **PROTAC**

Storage: Powder -20°C 3 years

 $4^{\circ}C$ 2 years

In solvent -80°C 6 months

> -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (562.32 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2493 mL	11.2463 mL	22.4926 mL
	5 mM	0.4499 mL	2.2493 mL	4.4985 mL
	10 mM	0.2249 mL	1.1246 mL	2.2493 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S) -AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein ^[1] . (S,R,S) -AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC ₅₀ <1 nM ^[2] .
IC ₅₀ & Target	VHL

EFERENCES				
Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-				
	Caution: Product has not been fully validated for medical applications. For research use only.			
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com			
	Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA			

Page 2 of 2 www.MedChemExpress.com